Paul Baehr
Chief Executive Officer at IBEX TECHNOLOGIES
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Belinda Franco | F | - | 4 years | |
| Robert de Luccia | M | 78 | 24 years | |
| Christine Charette | F | - | 3 years | |
| Antonio F. Cruz | M | 71 |
NeuroMedix, Inc.
 NeuroMedix, Inc. Pharmaceuticals: MajorHealth Technology NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada. | - |
| Danilo Netto | M | - | 17 years | |
| Bruce P. Connop | M | 55 | 7 years | |
| Joseph Zimmermann | M | - | 7 years | |
| Gary Pace | M | 76 |
NeuroMedix, Inc.
NeuroMedix, Inc. Pharmaceuticals: MajorHealth Technology NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada. | - |
| Calvin Stiller | M | 83 |
NeuroMedix, Inc.
NeuroMedix, Inc. Pharmaceuticals: MajorHealth Technology NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada. | - |
| Christopher M. Henley | M | 64 |
NeuroMedix, Inc.
NeuroMedix, Inc. Pharmaceuticals: MajorHealth Technology NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada. | - |
| Kevin L. Keim | M | - |
NeuroMedix, Inc.
NeuroMedix, Inc. Pharmaceuticals: MajorHealth Technology NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada. | - |
| Brian L. Mundell | M | - |
Bio-Research Products, Inc.
 Bio-Research Products, Inc. BiotechnologyHealth Technology Bio-Research Products, Inc. manufactures enzymes for biomedical manufacturing and research. It specializes in protein purification, characterization and analysis. The company was founded in 1975 and is headquartered in North Liberty, IA. | - |
| Phyllis C. Cunningham | F | - |
Bio-Research Products, Inc.
Bio-Research Products, Inc. BiotechnologyHealth Technology Bio-Research Products, Inc. manufactures enzymes for biomedical manufacturing and research. It specializes in protein purification, characterization and analysis. The company was founded in 1975 and is headquartered in North Liberty, IA. | - |
| Mahendra Pallapothu | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert A. Heft | M | 69 | 29 years | |
| Nancy Bisson | F | - | 6 years | |
| Bernard R. Patriacca | M | 79 | - | |
| Joseph G. Galli | M | - |
Haemacure Corp.
 Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 9 years |
| Lyne Paré | F | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 17 years |
| Gilles Lemieux | M | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 16 years |
| Richard Collin | M | - | 7 years | |
| King C. Lee | M | - | 3 years | |
| Marc Paquin | M | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 19 years |
| Wayne G. Johnson | M | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 19 years |
| Reinaldo Diaz | M | 70 |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 5 years |
| Cindy Patton | F | - |
Ciba-Geigy Corp.
| - |
| Dawn Benson | F | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | - |
| Pierre Alary | M | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 12 years |
| Christian Hours | M | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | - |
| Diane Roch | F | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | - |
| Alicia R. Lopez | F | 69 |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | - |
| Joseph C. Jones | M | 71 |
Ciba-Geigy Corp.
| 16 years |
| Joseph Akers | M | 78 |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 6 years |
| Neil Wiener | M | - |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 17 years |
| Michael Kishbauch | M | 75 |
Ciba-Geigy Corp.
| 10 years |
| Robin Hopper | M | - | 7 years | |
| Charles Emmett Pearson | M | - | 6 years | |
| John W. Gillard | M | - | - | |
| Thomas J. Lynch | M | 73 |
Haemacure Corp.
Haemacure Corp. Industrial SpecialtiesProcess Industries Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada. | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 34 | 87.18% |
| United States | 5 | 12.82% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Baehr
- Personal Network
